KEI Comments on NIH Exclusive License to Autala for Autoimmune Treatment

On September 3, 2024, Knowledge Ecology International (KEI) submitted comments to the NIH regarding the “Prospective Grant of an Exclusive Patent License: Dimethyl Synaptamide for the Treatment of Autoimmune Disorders and Inflammatory Diseases” (89 FR 66730). The Federal Register notice… Continue Reading

KEI Submissions to the NIH on the Draft NIH Intramural Research Program Policy: Promoting Equity Through Access Planning

The National Institutes of Health (NIH) Office of Science Policy (OSP) posted a Request for Information (RFI) on the Draft NIH Intramural Research Program Policy: Promoting Equity Through Access Planning. The draft policy seeks, “to promote access to products stemming… Continue Reading

KEI Comments on NIH License to McSAF for Antibody-Drug Conjugates for Cancer

Knowledge Ecology International (KEI) offered the following comments to the National Institutes of Health (NIH) concerning the “Prospective Grant of an Exclusive Patent License: Antibody-Drug Conjugates (ADCs) for Targeting CD56-Positive Tumors” (89 FR 40495) to McSAF Inside Oncology SAS (McSAF).… Continue Reading

KEI Comments on NIH Exclusive License to INTcRON

On Tuesday June 4, 2024, Knowledge Ecology International (KEI) submitted comments to the National Institutes of Health (NIH) regarding “Prospective Grant of an Exclusive Patent License: T Cell Receptor Fusion Proteins for the Treatment of Cancer” (89 FR 43859) to… Continue Reading

KEI Comments to the NIH on Exclusive License to UK Firm Poolbeg Pharma

On April 8, 2024, Knowledge Ecology International (KEI) submitted comments to the National Institutes of Health (NIH) regarding the prospective grant of an exclusive license to Poolbeg Pharma Limited, a UK-based company. The license concerns, “Adoptive T Cell Therapy Products… Continue Reading

KEI Comments to the NIH License on Gene Therapy to Marble Therapeutics

Today Knowledge Ecology International (KEI) submitted comments to the National Institutes of Health (NIH) regarding the “Prospective Grant of an Exclusive Patent License: Vaccine Augmented Adoptive Cell Therapy for the Treatment of Cancer” (89 FR 8438). The wordwide, exclusive license… Continue Reading

KEI Comment to NIST on the Bayh-Dole Letter to the Washington Post and the Legislative History of the Act

KEI submitted comments to the National Institute of Standards and Technology (NIST) issued a Request for Information regarding the “Draft Interagency Guidance Framework for Considering the Exercise of March-In Rights” (88 FR 85593) regarding the 2002 Bob Dole and Birch… Continue Reading

KEI Comment to NIST on “Available to the Public on Reasonable Terms”

On February 6, 2024, KEI submitted comments to the National Institute of Standards and Technology (NIST) regarding the Draft Interagency Guidance Framework for Considering the Exercise of March-In Rights (88 FR 85593). This set of comments outlined that the draft… Continue Reading